Future research should focus on unravelling mechanisms of primary and adaptive resistance, optimizing combination regimens, and stratifying patients based on CD226 expression, PD-L1 levels, and tumor immune contexture to fully harness the therapeutic potential of TIGIT inhibition. This evidence concerns the gene CD226 and neoplasm.